EFX | Jotup

AKRO EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

Retrieved on:

수요일, 5월 22, 2024

Class Action Lawsuit, Professional Services, Legal, Titan, Patient, Class, Food and Drug Administration, Advertising, Fatty liver disease, NASH, Cirrhosis, Court, EFX

WHAT TO DO NEXT: To join the Akero class action, go to https://rosenlegal.com/submit-form/?case_id=24557 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the Akero class action, go to https://rosenlegal.com/submit-form/?case_id=24557 or call Phillip Kim, Esq.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Kirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Retrieved on:

월요일, 5월 13, 2024

Class Action Lawsuit, Professional Services, Legal, Patient, News, Food and Drug Administration, Fatty liver disease, Research, NASH, Cirrhosis, Court, EFX, District court

Investors have until June 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until June 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Akero filed with the SEC a Form 8-K and issued a press release stating that the SYMMETRY study had failed to meet its primary endpoint.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
Additional information about the firm can be found at Kirby McInerney LLP’s website .

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

Retrieved on:

금요일, 5월 10, 2024

Class Action Lawsuit, Professional Services, Legal, Patient, News, Åkerö, Suite, FDA, NAFLD, NASH, Defendant, Cirrhosis, Court, EFX, Inflammation, GPM, Steatosis

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.
On this news, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share on October 10, 2023, thereby injuring investors.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

AKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Akero Therapeutics, Inc.

Retrieved on:

토요일, 5월 11, 2024

Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.

Key Points:

Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.
For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
If you choose to take no action, you can remain an absent class member.

Contact Hagens Berman by June 25, 2024 Deadline to Join Class Action Against Akero Therapeutics (AKRO)

Retrieved on:

목요일, 5월 9, 2024

FDA, Cirrhosis, EFX, Liver disease, News, Risk, Fatty liver disease, NASH, Patient, Failure, Hagens Berman, Clinical trial, Therapy, SAN, Person, Pharmaceutical industry

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses now .

Key Points:

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses now .
Akero Therapeutics, Inc. (AKRO) Securities Fraud Class Action:
Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is facing a securities class action lawsuit over allegations it misled investors about a key clinical trial.
The lawsuit centers on the SYMMETRY study, designed to evaluate efruxifermin ("EFX"), Akero's lead drug candidate, for treating nonalcoholic steatohepatitis (NASH), a serious liver condition.
"We are investigating whether Akero intentionally misrepresented its SYMMETRY patient population," stated Reed Kathrein, the Hagens Berman partner leading the investigation.

DEADLINE ALERT for ADSK, CMP, AKRO, EXAI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on:

수요일, 5월 8, 2024

FDA, Cirrhosis, Compass Minerals, Inflammation, NAFLD, Investment, EFX, Risk, Suite, Class, Steatosis, NASH, Law, Ethics, Patient, Defendant, Åkerö, Telephone, Knowledge

BENSALEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points:

BENSALEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
Investors have until the deadlines listed below to file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected] .
Law Offices of Howard G. Smith

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, Akero, and Equinix and Encourages Investors to Contact the Firm

Retrieved on:

수요일, 5월 8, 2024

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points:

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
Exscientia in an artificial intelligence ("AI") driven Pharma-tech company that engages in the design and develop differentiated medicines for diseases with high unmet patient needs.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
For more information on the Equinix class action go to: https://bespc.com/cases/EQIX

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Retrieved on:

수요일, 5월 8, 2024

Cirrhosis, LLP, EFX, Liver disease, News, Advertising, Fatty liver disease, NASH, Patient, Court, Fibrosis, Food and Drug Administration, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points:

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
In addition, Akero added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Akero’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

수요일, 5월 8, 2024

Sale, FDA, Cirrhosis, Inflammation, EFX, Liver disease, News, Complaint, Fatty liver disease, Research, Steatosis, NASH, Patient, Court, DSM-IV codes, Drug development, Person, Disclosure

The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.

Key Points:

The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.
To finance the Company’s operations, Akero conducted two secondary stock offerings and one at-the-market stock offering during the Class Period, raising over $577 million.
If you suffered a loss in Akero you have until June 25, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Akero Therapeutics, Inc.

Retrieved on:

화요일, 5월 7, 2024

FDA, Efficacy, Cirrhosis, Inflammation, LLP, NAFLD, EFX, Liver disease, Viability, Fatty liver disease, Steatosis, NASH, Complaint, Patient, DSM-IV codes, SAN, Person, Pharmaceutical industry

Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.

Key Points:

Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.
The Company is currently focused on advancing its lead product candidate efruxifermin (“EFX”) to provide a new treatment for patients with nonalcoholic steatohepatitis ("NASH"), a serious liver disease.
For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.